Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Barr Pharmaceuticals, a specialty pharmaceutical company, has confirmed that its subsidiary, Barr Laboratories, Inc, has initiated a challenge of the patents listed by Endo Pharmaceuticals in connection with its Opana extended-release tablets, 5mg, 10mg, 20mg and 40mg.
Subscribe to our email newsletter
Barr has filed its abbreviated new drug application (ANDA) containing a paragraph IV certification for a generic version of Opana ER with the FDA, and following receipt of the notice from the FDA that Barr’s ANDA had been accepted for filing, Barr notified the new drug application and patent holder.
On October 20, 2008, Endo Pharmaceuticals and Penwest Pharmaceuticals have filed suit in the US District Court of Delaware to prevent Barr from proceeding with the commercialization of its product. This action formally initiates the patent challenge process under the Hatch-Waxman Act.